Viva Biotech supercharges AI-driven drug discovery with NVIDIA tech
The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology
The move aims to accelerate drug discovery with AI-driven designs powered by NVIDIA technology
Artificial intelligence coupled with laboratory automation will transform how scientific work is performed
New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents
Designed as an “AI-as-a-Service” platform, VECURA aims to reduce the traditional therapeutic drug discovery timeline of 10–12 years to just a few hours.
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
This innovative solution comes as an answer to the industry-wide challenges of availability, cost, and dependencies linked to custom and proprietary hardware components
The facility features 2,176 high-performance GPUs across the US and Europe
LTTS’ lung digital twin integrates seamlessly with CT imaging workflows, using deep learning to reconstruct a comprehensive 3D digital twin of the lungs
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
Subscribe To Our Newsletter & Stay Updated